Identification

Name
Molindone
Accession Number
DB01618
Type
Small Molecule
Groups
Approved
Description

An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)

Structure
Thumb
Synonyms
  • (+-)-molindone
  • Molindona
  • Molindone
  • Molindonum
Product Ingredients
IngredientUNIICASInChI Key
Molindone hydrochloride1DWS68PNE615622-65-8GQWNECFJGBQMBO-UHFFFAOYSA-N
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Molindone HydrochlorideTablet5 mg/1OralCore Pharma, Llc2015-09-152017-08-15Us
Molindone HydrochlorideTablet25 mg/1OralCore Pharma, Llc2015-09-15Not applicableUs
Molindone HydrochlorideTablet10 mg/1OralCore Pharma, Llc2015-09-15Not applicableUs
International/Other Brands
Moban
Categories
UNII
RT3Y3QMF8N
CAS number
7416-34-4
Weight
Average: 276.374
Monoisotopic: 276.183778022
Chemical Formula
C16H24N2O2
InChI Key
KLPWJLBORRMFGK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
IUPAC Name
3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
SMILES
CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2

Pharmacology

Indication

Molindone is used for the management of the manifestations of psychotic disorders.

Structured Indications
Pharmacodynamics

Molindone is a dihydroindolone compound which is not structurally related to the phenothiazines, the butyrophenones, or the thioxanthenes. Molindone has a pharmacological profile in laboratory animals which predominantly resembles that of major tranquilizers causing reduction of spontaneous locomotion and aggressiveness, suppression of a conditioned response and antagonism of the bizarre stereotyped behavior and hyperactivity induced by amphetamines. In addition, molindone antagonizes the depression caused by the tranquilizing agent tetrabenazine.

Mechanism of action

The exact mechanism has not been established, however, based on electroencephalogram (EEG) studies, molindone is thought to act by occupying (antagonizing) dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Decreased dopamine activity results in decreased physiological effects normally induced by excessive dopamine stimulation, such as those typically seen in manifestations of psychotic disorders.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
UMuscarinic acetylcholine receptor M1
other/unknown
Human
Absorption

Rapidly absorbed from the gastrointestinal tract following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Most likely hepatic. 36 metabolites have been recognized, some of which may be active.

Route of elimination

Human metabolic studies show molindone to be rapidly absorbed and metabolized when given orally. There are 36 recognized metabolites with less than 2-3% unmetabolized molindone being excreted in urine and feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineMolindone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMolindone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMolindone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Molindone is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Molindone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Molindone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Molindone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Molindone is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Molindone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Molindone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Molindone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Molindone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Molindone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Molindone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Molindone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Molindone.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Molindone can be decreased when used in combination with Amantadine.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Molindone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Molindone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Molindone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Molindone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Molindone is combined with Amperozide.Experimental
AmphetamineMolindone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Molindone can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Molindone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Molindone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Azaperone.Investigational, Vet Approved
AzelastineMolindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Molindone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Molindone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Molindone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Molindone.Approved
BenzphetamineMolindone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Molindone is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Molindone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Molindone is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Molindone can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Molindone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Molindone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Molindone is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Molindone.Approved, Investigational
BuprenorphineMolindone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Molindone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Molindone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Molindone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Molindone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Molindone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Molindone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Molindone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Molindone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Molindone is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Molindone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Molindone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Molindone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Molindone is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Molindone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Molindone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Molindone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Molindone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Molindone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorphenamine.Approved
ChlorphentermineMolindone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Molindone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Molindone.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Molindone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Molindone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Molindone is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Molindone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Molindone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Molindone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Molindone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Molindone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Molindone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Molindone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Molindone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Molindone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Molindone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Molindone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Molindone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Molindone is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Molindone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Molindone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Molindone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Molindone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Molindone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Molindone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Molindone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Molindone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Molindone.Approved, Vet Approved
DextroamphetamineMolindone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Molindone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Molindone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Molindone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Molindone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Molindone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Molindone is combined with Diethyl ether.Experimental
DiethylpropionMolindone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Molindone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Molindone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Molindone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Molindone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Molindone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Molindone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Molindone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Molindone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Molindone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Molindone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Molindone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Molindone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Molindone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Molindone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Molindone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Molindone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Molindone is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Molindone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Molindone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Molindone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Molindone is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Molindone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Molindone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Molindone.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Molindone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Molindone.Approved
EthanolMolindone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Molindone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Molindone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Molindone is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Molindone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Molindone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Molindone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Molindone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Molindone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Molindone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Molindone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Molindone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Molindone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Molindone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Molindone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Molindone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Molindone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Molindone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Molindone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Molindone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Molindone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Molindone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Molindone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Molindone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Molindone.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Molindone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Molindone is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Molindone.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Molindone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Molindone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Molindone.Approved, Illicit, Investigational
GepefrineMolindone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Molindone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Molindone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Molindone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Molindone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Molindone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Molindone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Molindone.Approved
HydrocodoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.Approved, Illicit
HydroxyamphetamineMolindone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Molindone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Molindone is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Molindone is combined with Indiplon.Investigational
Iofetamine I-123Molindone may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Molindone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Molindone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Molindone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Molindone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Molindone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Molindone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Molindone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Molindone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Molindone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Molindone can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Molindone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Molindone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Molindone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Molindone.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Molindone.Approved, Investigational
LisdexamfetamineMolindone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Molindone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Molindone is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Molindone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Molindone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Molindone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Molindone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Molindone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Molindone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Molindone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Molindone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Molindone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Molindone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Molindone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Melperone.Approved, Investigational
MephedroneMolindone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineMolindone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Molindone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Molindone is combined with Meptazinol.Experimental
MequitazineMolindone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Molindone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Molindone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Molindone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Molindone.Approved, Illicit
MethamphetamineMolindone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Molindone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Molindone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Molindone.Approved
MethotrimeprazineMolindone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Molindone.Approved, Investigational, Vet Approved
MethoxyphenamineMolindone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Molindone is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Molindone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.Approved, Investigational
MetyrosineMolindone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.Approved, Illicit
MidomafetamineMolindone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Molindone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Investigational
MirtazapineMolindone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMolindone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Molindone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Molindone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Molindone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Molindone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Molindone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Molindone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Molindone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Molindone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Molindone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Molindone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Molindone.Approved
OpiumThe risk or severity of adverse effects can be increased when Molindone is combined with Opium.Approved, Illicit
OrphenadrineMolindone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Molindone is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Molindone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Molindone is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Molindone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Molindone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Molindone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Molindone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.Approved
ParaldehydeMolindone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Molindone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Molindone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
PerazineThe risk or severity of adverse effects can be increased when Molindone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Molindone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Molindone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Molindone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Molindone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Molindone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Molindone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Molindone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Molindone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Molindone is combined with Phenoxyethanol.Approved
PhentermineMolindone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Molindone is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Molindone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Molindone is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Molindone can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Molindone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Molindone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.Approved
PramipexoleMolindone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Molindone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Molindone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Molindone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Molindone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Molindone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Molindone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Molindone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Molindone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Molindone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Molindone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Molindone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Molindone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Molindone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Molindone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Molindone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Molindone is combined with PSD502.Investigational
PseudoephedrineMolindone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Molindone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Molindone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Molindone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Molindone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Molindone is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Molindone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Molindone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Molindone.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Molindone is combined with Ritanserin.Investigational
RitobegronMolindone may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Molindone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Molindone is combined with Romifidine.Vet Approved
RopiniroleMolindone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone.Approved
RotigotineMolindone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Molindone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Molindone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Molindone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Molindone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Molindone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Molindone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Molindone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Molindone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Molindone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Molindone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Molindone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Molindone.Approved, Investigational
SuvorexantMolindone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Molindone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Molindone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Molindone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Molindone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Molindone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Molindone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrodotoxin.Investigational
ThalidomideMolindone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Molindone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Molindone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Molindone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Molindone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Molindone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Molindone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Molindone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Molindone is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Molindone is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Molindone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Molindone is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Molindone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Molindone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Molindone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Molindone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Molindone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Molindone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Molindone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Molindone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Molindone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Molindone is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Molindone.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Molindone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Molindone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Molindone is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Molindone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Molindone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Molindone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Molindone is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Molindone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Molindone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Molindone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Molindone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Molindone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Molindone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Molindone.Approved, Investigational
ZolpidemMolindone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Molindone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Molindone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Molindone is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Molindone.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US3491093
General References
Not Available
External Links
Human Metabolome Database
HMDB15555
KEGG Compound
C07230
PubChem Compound
23897
PubChem Substance
46504744
ChemSpider
22342
BindingDB
50130290
ChEBI
6965
ChEMBL
CHEMBL460
Therapeutic Targets Database
DAP000979
PharmGKB
PA164746756
IUPHAR
207
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Molindone
ATC Codes
N05AE02 — Molindone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentImpulsive Aggression Comorbid With ADHD in Children1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Moban 50 mg tablet5.12USD tablet
Moban 25 mg tablet3.02USD tablet
Moban 10 mg tablet2.57USD tablet
Moban 5 mg tablet1.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.474 mg/mLALOGPS
logP2.09ALOGPS
logP2.04ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)15.34ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity81.06 m3·mol-1ChemAxon
Polarizability32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9637
Caco-2 permeable+0.6401
P-glycoprotein substrateSubstrate0.7994
P-glycoprotein inhibitor IInhibitor0.828
P-glycoprotein inhibitor IIInhibitor0.6826
Renal organic cation transporterInhibitor0.5863
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.637
CYP450 1A2 substrateNon-inhibitor0.6779
CYP450 2C9 inhibitorNon-inhibitor0.939
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.7549
CYP450 3A4 inhibitorInhibitor0.7739
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7134
Ames testNon AMES toxic0.6399
CarcinogenicityNon-carcinogens0.9336
BiodegradationNot ready biodegradable0.9909
Rat acute toxicity2.9352 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5259
hERG inhibition (predictor II)Inhibitor0.5804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.41 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indoles and derivatives. These are organic compounds containing an indole, which is a bicyclic ring system made up of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Not Available
Direct Parent
Indoles and derivatives
Alternative Parents
Aryl alkyl ketones / Aralkylamines / Substituted pyrroles / Morpholines / Vinylogous amides / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds
show 3 more
Substituents
Indole or derivatives / Aryl ketone / Aryl alkyl ketone / Aralkylamine / Morpholine / Oxazinane / Substituted pyrrole / Pyrrole / Heteroaromatic compound / Vinylogous amide
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indoles (CHEBI:6965)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Seeman P, Tallerico T: Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123-34. [PubMed:9577836]
  3. Lidow MS, Goldman-Rakic PS: Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther. 1997 Nov;283(2):939-46. [PubMed:9353417]
  4. Froimowitz M, Cody V: The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Drug Des Discov. 1997 Aug;15(2):63-81. [PubMed:9342550]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Nguyen TV, Juorio AV: Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):366-71. [PubMed:2586632]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Nguyen TV, Juorio AV: Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):366-71. [PubMed:2586632]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Neeper R, Richelson E, Nelson A: Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology. 1991 May;30(5):527-9. [PubMed:1678146]

Drug created on August 29, 2007 14:15 / Updated on December 01, 2017 17:21